RSLS OBALON THERAPEUTICS INC

ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations

ReShape Lifesciences Strengthens Leadership Team with Appointment of Michael Bordainick as Senior Vice President, Commercial Operations

Seasoned Executive Brings Significant Operational and Commercial Experience to Accelerate the Company’s Growth

SAN CLEMENTE, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced the appointment of Michael Bordainick as its Senior Vice President, Commercial Operations. In this newly created role, as part of the Company’s next phase of operational growth, Mr. Bordainick will be responsible for strengthening the strategic development and executional efficiencies of the sales and marketing teams.

“As Michael brings significant experience and capabilities to advance ReShape’s recently launched commercial programs, including direct-to-consumer marketing and enhanced support for our clinical customers, he will be a great addition to our executive team," stated Bart Bandy, President and Chief Executive Officer of ReShape Lifesciences. “We are confident that his previous successes with direct marketing and sales programs, both in healthcare and consumer product markets will translate meaningfully to our expanding commercial operations. Michael’s appointment reaffirms our ongoing focus and significant commitment to driving increased revenue through the targeted consumer marketing and sales programs behind Lap-Band®, reshapecare™ and our pipeline projects. Additionally, Michael’s previous success in mergers and acquisitions, capital investment and portfolio development activities will be highly advantageous to our company as we evaluate and pursue various strategic opportunities in those areas.”

“Reshape Lifesciences is well-positioned to address the growing global health and economic challenges associated with obesity. It is an exciting opportunity to represent the company’s portfolio of products and services that are anchored by the FDA-approved and widely reimbursed Lap-Band, the safest bariatric surgery procedure available with documented long-term clinical efficacy,” stated Mr. Bordainick. “Through the combination of the Lap-Band and reshapecare, the reimbursed virtual healthcare service dedicated to weight loss, we have the opportunity to help millions of individuals. I look forward to leading our commercial efforts to engage and educate more people on the benefits of these exceptional products and services.”

Mr. Bordainick has two decades of marketing and sales management experience in leading healthcare and consumer product industries. He joins Reshape from Alcon, where he served as Global Vice President of Marketing, responsible for marketing and sales activities of the company’s $1.8 billion contact lens portfolio. Prior to that, Mr. Bordainick was the Global Marketing Director at Kimberly Clark, where he led the Kleenex, Viva and Scott brands. Earlier in his career, he spent 10 years at Unilever, where he held positions of increasing responsibility within consumer brand management.

Mr. Bordainick holds a Bachelor of Business Administration in International Marketing and Finance from the University of Miami and an MBA from Indiana University’s Kelley School of Business.

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. For more information, please visit

Forward-Looking Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about our expectation that the marketing campaign will help us capitalize on our strong revenue potential. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTS:

Company Contact:

Thomas Stankovich

Chief Financial Officer

949-276-6042

Investor Relations Contact:

Rx Communications Group

Michael Miller

(917)-633-6086



EN
13/01/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OBALON THERAPEUTICS INC

 PRESS RELEASE

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting...

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or (from other countries) IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it conducted a Special Meeting of Sto...

 PRESS RELEASE

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural Lap-Band® Surgeon Summit, taking place August 1-3, 2025 in Nashville, Tennessee. Dr. Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program, and Chief of t...

 PRESS RELEASE

ReShape Lifesciences® to Host Special Meeting of Stockholders on July ...

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025 Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET on July 24, 2025. A...

 PRESS RELEASE

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric B...

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System Patent Enhances and Broadens the Company’s Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S. Patent and Trademark Office (USPTO) will issue U.S. Patent 12,350,179, entitled, “Intragastric Device.” The patent, related to the Company’s application 18/241,151 an...

 PRESS RELEASE

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockhold...

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market....

ResearchPool Subscriptions

Get the most out of your insights

Get in touch